Better Health for All

Bionano Genomics' core products, such as Optical Genome Mapping (OGM) systems and software, are designed to detect structural variants linked to diseases like cancer, rare genetic disorders, and reproductive health issues, with the stated mission to elevate human health and wellness.

The company's entire business is devoted to health improvement, with no evidence of products having negative health impacts. The company's products do not have direct physical or mental health safety implications for users. While OGM is described as having a 'comparatively cost-effective workflow,' no specific pricing data or affordability programs are provided. The company focuses on rare diseases, which affect 350 million people globally, but there is no evidence of the percentage of vulnerable populations reached. The company has a Code of Business Conduct and Ethics emphasizing compliance with ethical procedures and proper scientific conduct, and confidentiality of patient data, but lacks specific details on risk disclosures or data protection standards. The company develops OGM systems and software, but no specific percentage of R&D budget allocated to health improvement is provided. There is no evidence of significant health externalities from operations. The company supports the ACMG Foundation's Next Generation Fellowship & Residency Training Awards Program with three-year financial support, which aids in developing the genetics and genomics workforce. Bionano provides educational resources through blogs and events, but no specific funding or reach is detailed. The company's operations are not directly relevant to global health crisis response, mental health initiatives, or preventative health measures. The company emphasizes compliance with ethical procedures and proper scientific conduct, which implicitly relates to clinical trial ethics, but lacks specific details on ethical frameworks or inclusion practices.

Fair Pay & Worker Respect

Employee satisfaction is low, with an overall rating of 2.6 out of 5 stars based on 79 employee reviews, which is significantly below the Pharmaceutical & Biotechnology industry average of 3.5 stars.

Only 26% of employees would recommend the company to a friend, and 12% approve of the CEO. Employee feedback frequently cites issues with senior management, leadership, and a disorganized work environment, alongside mentions of frequent layoffs.

Fair Trade & Ethical Sourcing

Bionano Genomics has a Code of Business Conduct and Ethics that outlines a commitment to honest and ethical business practices, legal compliance, and fair dealing with suppliers.

The code details expectations for procurement, including supplier selection based on commercial considerations, and addresses gifts and entertainment. It also establishes a Compliance Officer and reporting mechanisms for violations, which are to be investigated promptly. The company has issued an inaugural ESG overview and plans to publish its first ESG report in the second half of 2023. However, the provided articles do not contain specific, measurable data points required to score any of the Fair Trade & Ethical Sourcing KPIs, such as fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage, materials risk index, or supplier diversity spend.

Honest & Fair Business

The company has a whistleblower policy that includes a third-party hotline for confidential and anonymous reporting, and employees can report suspected violations without fear of retaliation.

The Audit Committee is responsible for developing procedures for anonymous concerns regarding accounting or audit matters, and a Compliance Officer is expected to investigate reported violations promptly. The company reported material weaknesses in internal control over financial reporting as of December 31, 2019, due to insufficient resources and segregation of duties, though these did not result in material misstatements or changes to previously released financial results. The Board has determined that six directors are independent, but the percentage of independent directors is not provided. The company has adopted a Code of Business Conduct and Ethics that applies to all officers, directors, and employees, and it has an anti-corruption policy referencing compliance with the Foreign Corrupt Practices Act, but there is no mention of training frequency or effectiveness metrics. For the fiscal years ended December 31, 2019, and 2020, all hours expended on the financial audit were provided by the independent registered public accounting firm's full-time permanent employees, but the percentage of revenue, assets, or subsidiaries covered is not specified.

No War, No Weapons

No evidence was found in the provided articles regarding BNGO.US's involvement in arms manufacturing, military contracts, dual-use technology, sales to embargoed regimes, peacebuilding investments, or any other criteria related to the 'No War, No Weapons' ethical value. Article

pertained to a U.S. Army center and did not mention BNGO.US, while Article was a general legal notice for Bionano Genomics' website with no relevant data.

Planet-Friendly Business

Bionano Genomics lacks reported carbon emissions data, reduction targets, or climate pledges.

While the company stated a plan to publish an ESG report in the second half of 2023, no specific environmental metrics or quantitative data were provided in the available information. There is also no information on regulatory actions, violations, fines, or compliance issues. Product enhancements, such as increased reagent stability and sample processing capacity, were announced but do not constitute environmental performance metrics. Due to the absence of concrete, scorable environmental data, no KPIs can be assessed.

Respect for Cultures & Communities

The company has no reported cultural appropriation incidents, which aligns with its business model.

It provides a toll-free compliance hotline and a website for reporting violations, serving as a standard grievance mechanism. The company's Code of Business Conduct and Ethics requires prompt reporting of suspected or actual violations, with the Compliance Officer investigating these reports. New employees receive training on the Code policies, and annual training sessions are conducted to refresh employees' familiarity with the Code.

Safe & Smart Tech

Bionano Genomics has reported no material cybersecurity incidents.

The company's Compute On Demand service protects data via encryption, and the Code of Business Conduct and Ethics mandates employees protect confidential information. The company's privacy policy states that all data on its computing facilities is company property and subject to inspection, retention, and review, which limits user control. It also collects substantial unnecessary data, such as demographic and social media information, and retains data for legitimate business needs without specifying minimization practices or retention periods. Bionano Compute On Demand ensures data center compliance with IPAA, CSA, SOC2, and ITAR regulations, and the company increased compliance with regulations using Jscrambler for code protection. The Code of Business Conduct and Ethics also requires compliance with all applicable laws. The company mentions employee training, access controls, vulnerability assessments, scans, and penetration testing as security measures.

Zero Waste & Sustainable Products

The company has implemented waste reduction initiatives, specifically a new suite of sample preparation kits and detailed protocols designed to enable researchers to prepare samples with less waste.

For hazardous waste management, the company's Safety Data Sheet provides disposal instructions for hazardous materials and contaminated packaging, requiring adherence to all federal, state, and local environmental conditions. The company is committed to disposing of all waste through safe and responsible methods and expects employees to comply with all applicable environmental laws.